Vicore Pharma (VICO.ST)

Executive Summary

Vicore Pharma is a Swedish clinical-stage biotechnology company focused on developing innovative therapies for fibrotic and respiratory diseases. Its lead asset, C21, is an orally available angiotensin II type 2 receptor (AT2R) agonist with a novel mechanism of action that promotes tissue repair and antifibrotic effects. The company is currently advancing C21 in a Phase 2b trial (AIR) for idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease with high unmet need. Topline data from this study are expected in the second half of 2026 and represent a major value inflection point. Positive results could support accelerated regulatory pathways and potential partnering discussions. Additionally, Vicore is exploring C21 in other fibrotic indications such as systemic sclerosis and COVID-19-related fibrosis. The company is well-funded with a strong scientific team and a clear strategic focus on fibrosis. However, as a Phase 2-stage biotech, execution risk remains substantial, and the stock is subject to binary outcomes around data readouts.

Upcoming Catalysts (preview)

• H2 2026Phase 2b AIR trial topline data for C21 in IPF50% success
• 2026Potential licensing or partnership deal for ex-European rights30% success
• H2 2026Phase 2a proof-of-concept data for C21 in systemic sclerosis40% success